Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 3.25
BUR's Cash-to-Debt is ranked lower than
66% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. BUR: 3.25 )
Ranked among companies with meaningful Cash-to-Debt only.
BUR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.97  Med: No Debt Max: No Debt
Current: 3.25
Equity-to-Asset 0.69
BUR's Equity-to-Asset is ranked higher than
55% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. BUR: 0.69 )
Ranked among companies with meaningful Equity-to-Asset only.
BUR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.89 Max: 0.94
Current: 0.69
0.36
0.94
Piotroski F-Score: 4
Altman Z-Score: 2.15
Beneish M-Score: -4.16
WACC vs ROIC
18.45%
-387.25%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -5382.14
BUR's Operating Margin % is ranked lower than
89% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. BUR: -5382.14 )
Ranked among companies with meaningful Operating Margin % only.
BUR' s Operating Margin % Range Over the Past 10 Years
Min: -18770  Med: -6571.53 Max: -5382.14
Current: -5382.14
-18770
-5382.14
Net Margin % -5376.79
BUR's Net Margin % is ranked lower than
90% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. BUR: -5376.79 )
Ranked among companies with meaningful Net Margin % only.
BUR' s Net Margin % Range Over the Past 10 Years
Min: -18486.67  Med: -6270.75 Max: -5376.79
Current: -5376.79
-18486.67
-5376.79
ROE % -160.70
BUR's ROE % is ranked lower than
86% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. BUR: -160.70 )
Ranked among companies with meaningful ROE % only.
BUR' s ROE % Range Over the Past 10 Years
Min: -160.7  Med: -66.3 Max: -53.49
Current: -160.7
-160.7
-53.49
ROA % -110.57
BUR's ROA % is ranked lower than
85% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. BUR: -110.57 )
Ranked among companies with meaningful ROA % only.
BUR' s ROA % Range Over the Past 10 Years
Min: -113.74  Med: -63.24 Max: -48.16
Current: -110.57
-113.74
-48.16
ROC (Joel Greenblatt) % -1053.91
BUR's ROC (Joel Greenblatt) % is ranked lower than
61% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. BUR: -1053.91 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BUR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1207.15  Med: -961.88 Max: -398.4
Current: -1053.91
-1207.15
-398.4
3-Year Revenue Growth Rate 44.20
BUR's 3-Year Revenue Growth Rate is ranked higher than
85% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. BUR: 44.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BUR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 44.2
Current: 44.2
0
44.2
3-Year EBITDA Growth Rate 1.40
BUR's 3-Year EBITDA Growth Rate is ranked higher than
51% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. BUR: 1.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BUR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -15.6  Med: 1.4 Max: 326
Current: 1.4
-15.6
326
3-Year EPS without NRI Growth Rate 0.40
BUR's 3-Year EPS without NRI Growth Rate is ranked higher than
53% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. BUR: 0.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BUR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -18.1  Med: 0.4 Max: 323.6
Current: 0.4
-18.1
323.6
GuruFocus has detected 1 Warning Sign with Burcon NutraScience Corp $BUR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BUR's 10-Y Financials

Financials (Next Earnings Date: 2017-06-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with BUR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 3741
Compare:OTCPK:THCBF, AMEX:NBY, NAS:NTEC, OTCPK:CWBR, NAS:GNMX, OTCPK:TBQBF, NAS:MTFB, NAS:DRNA, NAS:GLMD, NAS:PBMD, OTCPK:ONCYF, NAS:OVAS, AMEX:PIP, NAS:VSTM, OTCPK:ZLDAF, NAS:KMPH, OTCPK:COTQF, NAS:ADMA, OTCPK:LVCLY, NAS:PULM » details
Traded in other countries:BU.Canada, BNE.Germany,
Burcon NutraScience Corp and its subsidiary are research and development companies that are developing plant protein extraction and purification technology in the field of functional, renewable plant proteins.

Burcon NutraScience Corp was incorporated on November 3, 1998. The Company, through its subsidiary, Burcon NutraScience (MB) Corp. is a research and development company building a portfolio of composition, application and process patents around its plant protein extraction and purification technology. The Company's products include CLARISOY, a soy protein isolate, which is used in various food products, including protein shakes, power bars, soups and sauces, meats and meat analogs, and breads and baked foods; and PEAZAZZ, a soluble pea protein isolate. Its products also comprise canola protein isolates, such as Supertein that comprises albumin proteins used in beverages, confectionery, aerated desserts, and protein bars; Puratein, which consists of globulin proteins used in dressings and sauces, meat substitutes, baked goods, and protein bars.

Ratios

vs
industry
vs
history
PB Ratio 14.15
BUR's PB Ratio is ranked lower than
90% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. BUR: 14.15 )
Ranked among companies with meaningful PB Ratio only.
BUR' s PB Ratio Range Over the Past 10 Years
Min: 7.95  Med: 16.44 Max: 86.58
Current: 14.15
7.95
86.58
PS Ratio 502.50
BUR's PS Ratio is ranked lower than
93% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. BUR: 502.50 )
Ranked among companies with meaningful PS Ratio only.
BUR' s PS Ratio Range Over the Past 10 Years
Min: 460  Med: 742.5 Max: 3540
Current: 502.5
460
3540
Current Ratio 2.47
BUR's Current Ratio is ranked lower than
67% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. BUR: 2.47 )
Ranked among companies with meaningful Current Ratio only.
BUR' s Current Ratio Range Over the Past 10 Years
Min: 0.82  Med: 9.45 Max: 55.01
Current: 2.47
0.82
55.01
Quick Ratio 2.47
BUR's Quick Ratio is ranked lower than
63% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. BUR: 2.47 )
Ranked among companies with meaningful Quick Ratio only.
BUR' s Quick Ratio Range Over the Past 10 Years
Min: 0.82  Med: 9.45 Max: 55.01
Current: 2.47
0.82
55.01
Days Sales Outstanding 162.95
BUR's Days Sales Outstanding is ranked lower than
87% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. BUR: 162.95 )
Ranked among companies with meaningful Days Sales Outstanding only.
BUR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 162.95  Med: 515.46 Max: 541.74
Current: 162.95
162.95
541.74

Buy Back

vs
industry
vs
history
5-Year Yield-on-Cost % 0.60
BUR's 5-Year Yield-on-Cost % is ranked lower than
81% of the 268 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. BUR: 0.60 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BUR' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 0.6
3-Year Average Share Buyback Ratio -3.90
BUR's 3-Year Average Share Buyback Ratio is ranked higher than
77% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. BUR: -3.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BUR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -42.4  Med: -5.7 Max: -2
Current: -3.9
-42.4
-2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 21.71
BUR's Price-to-Net-Cash is ranked lower than
82% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 6.36 vs. BUR: 21.71 )
Ranked among companies with meaningful Price-to-Net-Cash only.
BUR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.61  Med: 22.5 Max: 225
Current: 21.71
2.61
225
Price-to-Net-Current-Asset-Value 21.71
BUR's Price-to-Net-Current-Asset-Value is ranked lower than
87% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 5.79 vs. BUR: 21.71 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BUR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.56  Med: 21.31 Max: 134
Current: 21.71
2.56
134
Price-to-Tangible-Book 19.00
BUR's Price-to-Tangible-Book is ranked lower than
89% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. BUR: 19.00 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BUR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.43  Med: 14.91 Max: 1076.67
Current: 19
2.43
1076.67
Price-to-Median-PS-Value 0.68
BUR's Price-to-Median-PS-Value is ranked higher than
75% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. BUR: 0.68 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BUR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.68  Med: 1.07 Max: 4.05
Current: 0.68
0.68
4.05
Earnings Yield (Greenblatt) % -7.99
BUR's Earnings Yield (Greenblatt) % is ranked higher than
51% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. BUR: -7.99 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BUR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -11.1  Med: 0 Max: 0
Current: -7.99
-11.1
0

More Statistics

Revenue (TTM) (Mil) $0.09
EPS (TTM) $ -0.12
Beta1.03
Short Percentage of Float0.23%
52-Week Range $1.40 - 2.84
Shares Outstanding (Mil)37.83

Analyst Estimate

Mar17 Mar18
Revenue (Mil $) 2 9
EPS ($) -0.08 0.06
EPS without NRI ($) -0.08 0.06
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for BUR

Headlines

Articles On GuruFocus.com
Burelle: A Growing Euro for 50 cents Mar 12 2013 

More From Other Websites
Burcon NutraScience Corp. :BUR-US: Earnings Analysis: Q3, 2017 By the Numbers : March 20, 2017 Mar 20 2017
Burcon reports 3Q loss Feb 10 2017
Burcon reports 3Q loss Feb 10 2017
BURCON ANNOUNCES COMPLETION OF OVER-SUBSCRIBED RIGHTS OFFERING Dec 01 2016
Burcon NutraScience Corp. :BUR-US: Earnings Analysis: Q2, 2017 By the Numbers : November 29, 2016 Nov 29 2016
FIRST LARGE-SCALE CLARISOY™ PRODUCTION FACILITY FULLY COMMISSIONED Nov 08 2016
ETF’s with exposure to Burcon NutraScience Corp. : October 17, 2016 Oct 17 2016
ETF’s with exposure to Burcon NutraScience Corp. : October 5, 2016 Oct 05 2016
Burcon NutraScience Corp. :BUR-US: Earnings Analysis: Q1, 2017 By the Numbers : October 4, 2016 Oct 04 2016
FIRST LARGE-SCALE CLARISOY™ PRODUCTION FACILITY SCHEDULED TO BE COMMISSIONED IN FOURTH QUARTER Sep 06 2016
The Zacks Analyst Blog Highlights: Hershey's, Coach, Sysco, Burcon Nutrascience and Barfresh Food... Aug 12 2016
Consumer Stock Earnings Around the Corner: SYY, BUR, BRFH Aug 11 2016
Burford Capital Ltd. :BUR-GB: Earnings Analysis: For the six months ended June 30, 2016 : August 8,... Aug 08 2016
BURCON NUTRASCIENCE CORP Financials Aug 02 2016
Burcon NutraScience Corp. :BUR-US: Earnings Analysis: 2016 By the Numbers : July 26, 2016 Jul 26 2016
Burcon NutraScience Corp. :BUR-US: Earnings Analysis: Q4, 2016 By the Numbers : July 8, 2016 Jul 08 2016
BURCON ANNOUNCES FISCAL 2016 RESULTS AND REVIEWS OPERATIONS Jun 27 2016
BURCON ANNOUNCES CONVERTIBLE NOTE FINANCING Apr 07 2016
Burcon NutraScience Corp. :BUR-US: Earnings Analysis: Q3, 2016 By the Numbers Apr 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)